There are 2934 resources available
What benefit can we expect from emerging targeted agents including ICI to improve survival?
Presenter: Margaret Tempero
Session: ESMO Colloquium supported by Celgene - Pancreatic cancer: Can better understanding of biology improve resectability and survival?
Resources:
Slides
How far would you go in your treatment?
Presenter: Anna Sophie Berghoff
Session: The Hans Keulen Memorial Debate
Resources:
Slides
Webcast
Introduction
Presenter: Evandro de Azambuja
Session: ESMO Fellowship Programme
Resources:
Slides
Webcast
ESMO Fellowship programme: Practical tips from a former fellow
Presenter: Angela Lamarca
Session: ESMO Fellowship Programme
Resources:
Slides
Webcast
Best ESMO Fellowship Project
Presenter: Antonio Di Meglio
Session: ESMO Fellowship Programme
Resources:
Slides
Webcast
Best Publication deriving from an ESMO Fellowship
Presenter: Valentina Gambardella
Session: ESMO Fellowship Programme
Resources:
Slides
Webcast
6136 - Clinical Outcomes by Chemotherapy Regimen in Patients with RS 26-100 in TAILORx
Presenter: Joseph Sparano
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
4667 - Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
Presenter: Michael Untch
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
4794 - INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ripretinib as _4th-Line Therapy In Patients With AdvanCed Gastrointestinal Stromal TUmorS (GIST) Who have Received Treatment With Prior Anticancer Therapies (NCT03353753)
Presenter: Margaret von Mehren
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
1292 - Results of the randomized, Placebo (PL)-controlled Phase II study evaluating the efficacy and safety of Regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed Chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and Unicancer
Presenter: Florence Duffaud
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast